AIMS: This review evaluates the literature on the prognostic value of in-treatment tumor response measurements during radiotherapy for head and neck cancer, assessing the most commonly used imaging modalities through meta-analysis. MATERIALS AND METHODS: A systematic literature search was conducted following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. Studies correlating in-treatment tumor response during radiotherapy with clinical endpoints such as loco-regional control (LRC) or overall survival (OS) were included. Meta-analyses were performed for comparable hazard ratios (HR) using the random-effects model. RESULTS: F-fluorodeoxy-d-glucose positron emission tomography (FDG-PET) (32 studies), magnetic resonance imaging (MRI) (31 studies), and computed tomography (CT) (11 studies) were the most frequently used modalities. Meta-analysis showed that a low tumor volume reduction rate on CT was strongly associated with poorer LRC (HR: 4.6). High SUVmax on FDG-PET during treatment was a significant prognostic marker for both poorer OS (HR: 1.97) and LRC (HR: 1.72). In contrast, changes in apparent diffusion coefficient (ADC) on MRI showed no significant prognostic value for LRC (HR: 0.97). Only 19.4% of studies could be included in the meta-analyses due to missing data. Attempts to retrieve additional information from authors were largely unsuccessful. CONCLUSION: Tumor volume reduction rate on CT and SUVmax on FDG-PET are promising prognostic markers for treatment response during radiotherapy in head and neck cancer. ADC measurements from MRI show limited prognostic value.
No takes yet. Share an insight, caveat, or question.
Poulsen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: